(s)-(N-(4-fluorophenyl)-N'-[(2-fluoro-4-pyridyl)methyl]-N''-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride)

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (s)-(N-(4-fluorophenyl)-N'-[(2-fluoro-4-pyridyl)methyl]-N''-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride)
• 英文别名: N-(4-fluorophenyl)-N'-[(2-fluoro-4-pyridyl)methyl]-N''-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride；2-N-(4-fluorophenyl)-6-N-[(2-fluoropyridin-4-yl)methyl]-4-N-phenyl-1,3,5-triazine-2,4,6-triamine;hydrochloride
• 化学式: C₂₁H₁₇F₂N₇*ClH
• 分子量: 441.871
• InChiKey: KGEZCAFACASJEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.07
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  87.6
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA
  申请人：TAKAHASHI Shinji

  公开号：US20100256152A1

  公开（公告）日：2010-10-07

  The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of schizophrenia, containing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of the positive symptoms, negative symptoms, cognitive impairments and the like of schizophrenia.

  本发明有助于提供一种优秀的药物组合，用于预防和/或治疗精神分裂症，其包含BEC1钾通道抑制剂或其药学上可接受的盐作为活性成分，特别适用于提供一种预防和/或治疗精神分裂症的阳性症状、阴性症状、认知障碍等的药物组合。
• COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA
  申请人：Astellas Pharma Inc.

  公开号：EP2413940A1

  公开（公告）日：2012-02-08
• [EN] COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA<br/>[FR] COMPOSITIONS COMPRENANT DES DERIVES DE 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE POUR LE TRAITEMENT DE LA SCHIZOPHRENIE
  申请人：ASTELLAS PHARMA INC

  公开号：WO2010114163A1

  公开（公告）日：2010-10-07

  The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of schizophrenia, containing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of the positive symptoms, negative symptoms, cognitive impairments and the like of schizophrenia.